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Abstract
The Juvenile Arthritis Multidimensional Assessment Report (JAMAR) is a new parent/patient reported outcome measure that 
enables a thorough assessment of the disease status in children with juvenile idiopathic arthritis (JIA). We report the results 
of the cross-cultural adaptation and validation of the parent and patient versions of the JAMAR in the Latvian language. 
The reading comprehension of the questionnaire was tested in 10 JIA parents and patients. Each participating centre was 
asked to collect demographic, clinical data and the JAMAR in 100 consecutive JIA patients or all consecutive patients seen 
in a 6-month period and to administer the JAMAR to 100 healthy children and their parents. The statistical validation phase 
explored descriptive statistics and the psychometric issues of the JAMAR: the three Likert assumptions, floor/ceiling effects, 
internal consistency, Cronbach’s alpha, interscale correlations, test–retest reliability, and construct validity (convergent and 
discriminant validity). A total of 100 JIA patients (2% systemic, 56% oligoarticular, 17% RF negative polyarthritis, 25% 
other categories) and 204 healthy children, were enrolled at the paediatric rheumatology centre. The JAMAR components 
discriminated healthy subjects from JIA patients, except for the paediatric rheumatology quality of life (HRQoL), psycho-
social health (PsH) subscales, the HRQoL total score and for the school-related problems variable. All JAMAR components 
revealed good psychometric performances. In conclusion, the Latvian version of the JAMAR is a valid tool for the assessment 
of children with JIA and is suitable for use both in routine clinical practice and clinical research.
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Introduction
The aim of the present study was to cross-culturally adapt 
and validate the Latvian parent, child/adult version of the 
Juvenile Arthritis Multidimensional Assessment Report 
(JAMAR) [1] in patients with juvenile idiopathic arthritis 
(JIA). The JAMAR assesses the most relevant parent/patient 
reported outcomes in JIA, including overall well-being, 
functional status, health-related quality of life (HRQoL), 
pain, morning stiffness, disease activity/status/course, 
articular and extra-articular involvement, drug-related side 
effects/compliance and satisfaction with illness outcome.
This project was part of a larger multinational study con-
ducted by the Paediatric Rheumatology International Trials 
Organisation (PRINTO) [2] aimed to evaluate the epidemiol-
ogy, outcome and treatment of childhood arthritis (EPOCA) 
in different geographic areas [3].
We report herein the results of the cross-cultural adapta-
tion and validation of the parent and patient versions of the 
JAMAR in the Latvian language.
Materials and methods
The methodology employed has been described in detail in 
the introductory paper of the supplement [4]. In brief, it was 
a cross-sectional study of JIA children, classified according 
to the ILAR criteria [5, 6] and enrolled from May 2012 to 
August 2012. Children were recruited after Ethics Commit-
tee approval and consent from at least one parent.
The JAMAR
The JAMAR [1] includes the following 15 sections:
 1. Assessment of physical function (PF) using 15-items 
in which the ability of the child to perform each task is 
scored as follows: 0 = without difficulty, 1 = with some 
difficulty, 2 = with much difficulty, 3 = unable to do and 
not applicable if it was not possible to answer the ques-
tion or the patient was unable to perform the task due 
to their young age or to reasons other than JIA. The 
total PF score ranges from 0 to 45 and has 3 compo-
nents: PF-lower limbs (PF -LL); PF-hand and wrist 
(PF -HW) and PF-upper segment (PF-US) each scor-
ing from 0 to 15 [7]. Higher scores indicating higher 
degree of disability [8–10].
 2. Rating of the intensity of the patient’s pain on a 
21-numbered circle visual analogue scale (VAS) [11].
 3. Assessment of the presence of joint pain or swelling 
(present/absent for each joint).
 4. Assessment of morning stiffness (present/absent).
 5. Assessment of extra-articular symptoms (fever and 
rash) (present/absent).
 6. Rating of the level of disease activity on a 21-circle 
VAS.
 7. Rating of disease status at the time of the visit (cat-
egorical scale).
 8. Rating of disease course from previous visit (categori-
cal scale).
 9. Checklist of the medications the patient is taking (list 
of choices);
 10. Checklist of side effects of medications.
 11. Report of difficulties with medication administration 
(list of items).
 12. Report of school/university/work problems caused by 
the disease (list of items).
 13. Assessment of HRQoL, through the physical health 
(PhH), and psychosocial health (PsH) subscales (5 
items each) and a total score. The four-point Likert 
response, referring to the prior month, are ‘never’ 
(score = 0), ‘sometimes’ (score = 1), ‘most of the time’ 
(score = 2) and ‘all the time’ (score = 3). A ‘not assess-
able’ column was included in the parent version of the 
questionnaire to designate questions that cannot be 
answered because of developmental immaturity. The 
total HRQoL score ranges from 0 to 30, with higher 
scores indicating worse HRQoL. A separate score for 
PhH and PsH (range 0–15) can be calculated. [12–14].
 14. Rating of the patient’s overall well-being on a 21-num-
bered circle VAS.
 15. A question about satisfaction with the outcome of the 
illness (Yes/No) [15].
The JAMAR is available in three versions, one for parent 
proxy-report (child’s age 2–18), one for child self-report, 
with the suggested age range of 7–18 years, and one for 
adults.
Cross‑cultural adaptation and validation
The process of cross-cultural adaptation was conducted 
according to international guidelines with 2–3 forward and 
backward translations. In those countries for which the trans-
lation of JAMAR had been already cross-cultural adapted in 
a similar language (i.e., Spanish in South American coun-
tries), only the probe technique was performed. Reading 
comprehension and understanding of the translated ques-
tionnaires were tested in a probe sample of ten JIA parents 
and ten patients.
Each participating centre was asked to collect demo-
graphic, clinical data and the JAMAR in 100 consecutive 
JIA patients or all consecutive patients seen in a 6-month 
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period and to administer the JAMAR to 100 healthy chil-
dren and their parents.
The statistical validation phase explored the descrip-
tive statistics and the psychometric issues [16]. In par-
ticular, we evaluated the following validity components: 
the first Likert assumption [mean and standard deviation 
(SD) equivalence]; the second Likert assumption or equal 
items-scale correlations (Pearson r: all items within a scale 
should contribute equally to the total score); third Lik-
ert assumption (item internal consistency or linearity for 
which each item of a scale should be linearly related to the 
total score that is 90% of the items should have Pearson 
r ≥ 0.4); floor/ceiling effects (frequency of items at lower 
and higher extremes of the scales, respectively); internal 
consistency, measured by the Cronbach’s alpha, interscale 
correlation (the correlation between two scales should 
be lower than their reliability coefficients, as measured 
by Cronbach’s alpha); test–retest reliability or intraclass 
correlation coefficient (reproducibility of the JAMAR 
repeated after 1 or 2 weeks); and construct validity in its 
two components: the convergent or external validity which 
examines the correlation of the JAMAR subscales with 
the 6 JIA core set variables, with the addition of the par-
ent assessment of disease activity and pain by the Spear-
man’s correlation coefficients (r) [17] and the discriminant 
validity, which assesses whether the JAMAR discriminates 
between the different JIA categories and healthy children 
[18].
Quantitative data were reported as medians with 1st and 
3rd quartiles and categorical data as absolute frequencies 
and percentages.
The complete Latvian parent and patient versions of the 
JAMAR are available upon request to PRINTO.
Results
Cross‑cultural adaptation
The Latvian JAMAR was fully cross-culturally adapted 
with 2 forward and 2 backward translations with a con-
cordance for 100/123 translations lines (81.3%) for the 
parent version and 106/120 lines (88.3%) for the child 
version.
In the probe technique analysis, all the 123 lines of 
the parent version of the JAMAR were understood by at 
least 80% of the 10 parents tested (median = 100%; range 
90–100%). All the 120 lines of the patient version of the 
JAMAR were understood by at least 80% of the children 
(median = 100%; range 90–100%). The text of the parent 
and patient version of the JAMAR was unmodified after the 
probe technique.
Demographic and clinical characteristics 
of the subjects
A total of 100 JIA patients and 204 healthy children (total 
of 304 subjects) were enrolled at the paediatric rheumatol-
ogy centre.
In the 100 JIA subjects, the JIA categories were 2.0% with 
systemic arthritis, 56.0% with oligoarthritis, 17.0% with RF 
negative polyarthritis, 13.0% with RF positive polyarthritis, 
4.0% with psoriatic arthritis, 7.0% with enthesitis-related 
arthritis and 1.0% with undifferentiated arthritis (Table 1).
A total of 205/304 (67.4%) subjects had the parent ver-
sion of the JAMAR completed by a parent (100 from parents 
of JIA patients and 105 from parents of healthy children). 
The JAMAR was completed by 185/205 (90.2%) mothers 
and 20/205 (9.8%) fathers. The child version of the JAMAR 
was completed by 170/304 (55.9%) children age 7.9 or older.
Discriminant validity
The JAMAR results are presented in Table 1, including 
the scores (median (1st–3rd quartile)) obtained for the PF, 
the PhH, the PsH subscales and total score of the HRQoL 
scales. The JAMAR components discriminated well between 
healthy subjects and JIA patients.
In summary, the JAMAR revealed that JIA patients had 
a greater level of disability and pain, as well as a lower 
HRQoL than their healthy peers. However, there was no 
significant difference between healthy subjects and their 
affected peers in school-related item and in PsH subscale 
and in the total score of HRQoL.
Psychometric issues
The main psychometric properties of both parent and child 
versions of the JAMAR are reported in Table 2. The follow-
ing “Results” section refers mainly to the parent’s version 
findings, unless otherwise specified.
Descriptive statistics (first Likert assumption)
There were no missing results for all JAMAR items, since data 
were collected through a web-based system that did not allow 
to skip answers and input null values. The response pattern 
for both PF and HRQoL was positively skewed toward normal 
functional ability and normal HRQoL. All response choices 
were used for the different HRQoL items except for items 8 
and 10, whereas a reduced number of response choices was 
used for all the PF items except for items 1, 3, 4, 5, 8 and 10.
The mean ± SD of the items within a scale were roughly 
equivalent for the PF (except for item 5) and for the HRQoL 
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Table 1  Descriptive statistics (medians, 1st and 3rd quartiles or absolute frequencies and %) for the 100 JIA patients
Data related to the JAMAR refers to the 100 JIA patients and to the 105 healthy subjects for whom the questionnaire has been completed by the 
parents
JAMAR, Juvenile Arthritis Multidimensional Assessment Report; ESR, erythrocyte sedimentation rate; MD, medical doctor; VAS, visual ana-
logue scale (score 0–10; 0 = no activity, 10 = maximum activity); LOM, limitation of motion; ANA, anti-nuclear antibodies; PF, physical func-
tion (total score ranges from 0 to 45); HRQoL, health-related quality of life (total score ranges from 0 to 30); PhH, physical health (total score 
ranges from 0 to 15); PsH, psychosocial health (total score ranges from 0 to 15)
p values refers to the comparison of the different JIA categories or to JIA versus healthy. *p < 0.05, **p < 0.001, #p < 0.0001
Systemic Oligoarthritis RF − Polyar-
thritis
RF + Polyar-
thritis
Psoriatic 
arthritis
Enthesitis-
related 
arthritis
Undifferenti-
ated arthritis
All JIA 
patients
Healthy
N = 2 N = 56 N = 17 N = 13 N = 4 N = 7 N = 1 N = 100 N = 204
Female 1 (50%) 34 (60.7%) 11 (64.7%) 9 (69.2%) 3 (75%) 1 (14.3%) 0 (0%) 59 (59%) 106 (52%)
Age at visit 7.2 (6.2–8.2) 11 (7.9–15.4) 12.2 (10.9–
16.9)
14.2 
(12.2–15)
11.1 
(9.6–12.6)
11 (6.2–12.2) 13.2 (13.2–
13.2)
11.9 (9.2–15) 7.9 (4–9.9)#
Age at onset 4.4 (4.2–4.7) 7 (3.9–10.2) 8 (5–10) 10.2 
(9.1–12.6)
9.6 (7.1–11.3) 4.6 (4.6–7.5) 9.4 (9.4–9.4) 7.6 (4.6–10.5)
Disease duration 2.7 (1.5–4) 3.3 (2–5.9) 5.2 (2.5–7.3) 3.9 (0.7–5.2) 1.8 (1.3–2.5) 1.7 (1.6–6.6) 3.7 (3.7–3.7) 3.3 (1.9–5.9)
ESR 30 (15–45) 7 (3–19) 15 (6–20) 32 (21–36) 7 (2–20) 6 (2–18) 12 (12–12) 12 (4–21)*
MD VAS 8 (8–8) 4 (3–5) 4 (2–5) 7 (4–9) 4 (2–7) 3.5 (2.5–4.5) (–) 4 (3–5)
No. swollen joints 4 (4–4) 0 (0–1.5) 2 (0–8) 11 (8–12) 3 (1-4.5) 0 (0–2) 4 (4–4) 1 (0–4)#
No. joints with 
pain
2.5 (0–5) 3 (2–4) 9 (5–13) 12 (9–15) 7 (4–10) 4 (4–5) 5 (5–5) 4 (2–8)#
No. joints with 
LOM
4.5 (4–5) 0.5 (0–2) 5 (1–10) 12 (11–14) 6 (3–14) 3 (2–5) 16 (16–16) 2 (0–6)#
No. active joints 4.5 (4–5) 1.5 (0–3.5) 5 (1–10) 12 (9–16) 4.5 (3–7) 3 (3–5) 8 (8–8) 3 (0–6)#
Active systemic 
features
1 (50%) 2 (3.6%) 0 (0%) 1 (7.7%) 0 (0%) 0 (0%) 0 (0%) 4 (4%)#
ANA status 0 (0%) 7 (12.5%) 2 (11.8%) 4 (30.8%) 0 (0%) 0 (0%) 1 (100%) 14 (14%)
Uveitis 0 (0%) 5 (8.9%) 0 (0%) 1 (7.7%) 0 (0%) 1 (14.3%) 0 (0%) 7 (7%)
PF total score 12.5 (0–25) 2 (0–3) 5 (3–8) 9 (2–16) 2 (1–4) 3 (0–5) 0 (0–0) 2.5 (0–5)* 0 (0–0)#
Pain VAS 5 (1–9) 3 (1.5–4.5) 4 (1-5.5) 5 (3–7) 4.5 (3.3–5.5) 3 (1.5–3.5) 0.5 (0.5–0.5) 3.5 (1.8-5) 0 (0–0)#
Disease activity 
VAS
4.8 (1–8.5) 2.8 (1-4.5) 4 (1.5-6) 6 (5–8) 3.3 (1.3–5.3) 3.5 (2.5-5) 0 (0–0) 3.5 (1.3–5.5)*
Well-being VAS 5.8 (2.5-9) 3 (1-4.3) 3.5 (1-5.5) 6 (3.5-8) 3 (1.8–4.5) 3 (2–5) 0 (0–0) 3 (1.5-5)*
HRQoL PhH 5 (2–8) 2 (1–4) 3 (2–6) 6 (2–7) 2.5 (1.5–4.5) 2 (1–4) 0 (0–0) 2 (1–4.5) 0 (0–5)#
HRQoL PsH 6.5 (4–9) 1 (0-3.5) 3 (1–6) 2 (0–4) 2 (0–7) 2 (0–5) 0 (0–0) 2 (0–5) 1 (0–3)
HRQoL total 
score
11.5 (6–17) 4 (1–7) 8 (3–11) 8 (4–10) 4.5 (1.5–11.5) 6 (1–6) 0 (0–0) 5 (2–8) 3 (0–99)
Pain/swell. in > 1 
joint
1 (50%) 50 (89.3%) 15 (88.2%) 13 (100%) 4 (100%) 5 (71.4%) 0 (0%) 88 (88%) 0 (0%)#
Morning stiff-
ness > 15 min
1 (50%) 17 (30.4%) 10 (58.8%) 11 (84.6%) 2 (50%) 2 (28.6%) 0 (0%) 43 (43%) 0 (0%)#
Subjective remis-
sion
2 (100%) 39 (69.6%) 13 (76.5%) 12 (92.3%) 3 (75%) 4 (57.1%) 0 (0%) 73 (73%)
In treatment 2 (100%) 41 (73.2%) 15 (88.2%) 12 (92.3%) 4 (100%) 6 (85.7%) 0 (0%) 80 (80%)
Reporting side 
effects
1 (50%) 4/41 (9.8%) 2/15 (13.3%) 3/12 (25%) 0 (0%) 1/6 (16.7%) – 11/80 (13.8%)
Taking medica-
tion regularly
2 (100%) 39/41 (95.1%) 15/15 (100%) 11/12 (91.7%) 4 (100%) 6/6 (100%) – 77/80 (96.3%)
With problems 
attending school
1/1 (100%) 4/34 (11.8%) 1/12 (8.3%) 0 (0%) 1/3 (33.3%) 1/5 (20%) 0 (0%) 8/60 (13.3%) 0 (0%)
Satisfied with dis-
ease outcome
1 (50%) 42 (75%) 8 (47.1%) 3 (23.1%) 3 (75%) 5 (71.4%) 1 (100%) 63 (63%)
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items (except for items 3 and 5) (data not shown). The 
median number of items marked as not applicable was 1.0% 
(1–1.0%) for the PF and 1.0% (1–2.0%) for the HRQoL.
Floor and ceiling effect
The median floor effect was 85.0% (65–93%) for the PF 
items, 58% (33–63%) for the HRQoL PhH items, and 62% 
(54–68%) for the HRQoL PsH items. The median ceiling 
effect was 0% (0–1%) for the PF items, 2% (1–2%) for 
the HRQoL PhH items, and 1% (0–1%) for the HRQoL 
PsH items. The median floor effect was 5% for the pain 
VAS, 13% for the disease activity VAS and 9% for the 
well-being VAS. The median ceiling effect was 1% for the 
pain VAS, 0% for the disease activity VAS and 0% for the 
well-being VAS.
Table 2  Main psychometric characteristics between the parent and child version of the JAMAR
JAMAR Juvenile Arthritis Multidimensional Assessment Report, JIA juvenile idiopathic arthritis, VAS visual analogue scale, PF physical func-
tion, HRQoL health-related quality of life; PhH: physical health, PsH psychosocial health, PF-LL PF-lower limbs, PF-HW PF-hand and wrist, 
PF-US PF-upper segment
Parent N = 100/205 Child N = 71/170
Missing values (1st–3rd quartiles) No missing values No missing values
Response pattern PF and HRQoL positively skewed PF and HRQoL positively skewed
Floor effect, median
 PF 85.0% 80.3%
 HRQoL PhH 58.0% 59.2%
 HRQoL PsH 62.0% 74.6%
 Pain VAS 5.0% 5.6%
 Disease activity VAS 13.0% 14.1%
 Well-being VAS 9.0% 11.3%
Ceiling effect, median
 PF 0.0% 1.4%
 HRQoL PhH 2.0% 2.8%
 HRQoL PsH 1.0% 1.4%
 Pain VAS 1.0% 0.0%
 Disease activity VAS 0.0% 0.0%
 Well-being VAS 0.0% 0.0%
Items with equivalent item-scale correlation 87% for PF, 80% for HRQoL 87% for PF, 100% for HRQoL
Items with items-scale correlation ≥ 0.4 87% for PF, 100% for HRQoL 100% for PF, 100% for HRQoL
Cronbach’s alpha
 PF-LL 0.81 0.85
 PF-HW 0.93 0.94
 PF-US 0.78 0.93
 HRQoL-PhH 0.83 0.85
 HRQoL-PsH 0.89 0.92
Items with item-scale correlation lower than the Cronbach alpha 93% for PF, 100% for HRQoL 100% for PF, 100% for HRQoL
Test–retest intraclass correlation
 PF total score 1.0 1.0
 HRQoL-PhH 1.0 1.0
 HRQoL-PsH 1.0 1.0
Spearman correlation with JIA core set variables, median
 PF 0.3 0.5
 HRQoL PhH 0.3 0.4
 HRQoL PsH 0.2 0.4
 Pain VAS 0.4 0.5
 Disease activity VAS 0.4 0.5
 Well-being VAS 0.4 0.5
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Equal items‑scale correlations (second Likert 
assumption)
Pearson items-scale correlations corrected for overlap were 
roughly equivalent for items within a scale for 87% of the PF 
items, with the exception of PF items 5 and 15, and for 80% 
of the HRQoL items, with the exception of items 5 and 10.
Items internal consistency (third Likert assumption)
Pearson items-scale correlations were ≥ 0.4 for 87% of items 
of the PF (except for PF items 5 and 15) and 100% of items 
of the HRQoL.
Cronbach’s alpha internal consistency
Cronbach’s alpha was 0.81 for PF-LL, 0.93 for PF-HW, 0.78 
for PF-US. Cronbach’s alpha was 0.83 for HRQoL-PhH and 
0.89 for HRQoL-PsH.
Interscale correlation
The Pearson correlation of each item of the PF and the 
HRQoL with all items included in the remaining scales of 
the questionnaires was lower than the Cronbach’s alpha, 
except for the PF item 13.
Test–retest reliability
Reliability was assessed in 10 JIA patients, by re-adminis-
tering both versions (parent and child) of JAMAR after a 
median of 7 days (7–7 days). The intraclass correlation coef-
ficients (ICC) for the PF total score showed an almost perfect 
reproducibility (ICC = 1.0). The ICC for the HRQoL PhH 
and for the HRQoL PsH showed an almost perfect reproduc-
ibility (ICC = 1.0 for both).
Convergent validity
The Spearman correlation of the PF total score with the 
JIA core set of outcome variables ranged from 0.3 to 0.7 
(median = 0.3). The PF total score best correlation was 
observed with the disease activity VAS (r = 0.8, p < 0.001). 
For the HRQoL, the median correlation of the PhH with 
the JIA core set of outcome variables ranged from 0.2 to 
0.5 (median = 0.3), whereas PsH ranged from 0.04 to 0.3 
(median = 0.2). The PhH showed the best correlation with 
the parent’s assessment of pain (r = 0.6, p < 0.001) and the 
PsH showed the best correlation with the parent’s assess-
ment of well-being (r = 0.3, p = 0.0004). The median cor-
relations between the pain VAS, the well-being VAS, and 
the disease activity VAS and the physician-centred and 
laboratory measures were 0.4 (0.4–0.5), 0.4 (0.4–0.5), 0.4 
(0.4–0.5), respectively.
Discussion
In this study, the Latvian version of the JAMAR was cross-
culturally adapted from the original standard English version 
with 2 forward and 2 backward translations. According to 
the results of the validation analysis, the Latvian parent and 
patient versions of the JAMAR possess satisfactory psycho-
metric properties. The disease-specific components of the 
questionnaire discriminated well between patients with JIA 
and healthy controls. Notably, there was no significant dif-
ference between the healthy subjects and their affected peers 
in the psychosocial quality of life and in the total score of 
HRQoL and school-related problems. These findings indi-
cates that children with JIA adapt well to the consequences 
of JIA, and have school performances comparable to those of 
their healthy peers. The functional ability questionnaire PF 
revealed to be able to discriminate between the different JIA 
subtypes with the children diagnosed with systemic arthritis 
having a higher degree of disability.
Psychometric evaluation was good for all domains with 
few exceptions: 2 PF items (bend down and bite a sand-
wich or an apple) showed a lower items internal consistency. 
However, the overall internal consistency was good for all 
the domains.
In the external validity evaluation, the Spearman’s cor-
relations of the PF and HRQoL scores with JIA core set 
parameters ranged from weak to moderate.
The results obtained for the parent version of the JAMAR 
are very similar to those obtained for the child version, 
which suggests that children are equally reliable proxy 
reporters of their disease and health status as their parents.
The JAMAR is aimed to evaluate the side effects of medi-
cations and school attendance, which are other dimensions 
of daily life that were not previously considered by other 
HRQoL tools. This may provide useful information for inter-
vention and follow-up in health care.
In conclusion, the Latvian version of the JAMAR was 
found to have satisfactory psychometric properties and it 
is, thus, a reliable and valid tool for the multidimensional 
assessment of children with JIA.
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